Lisdexamfetamine Dimesylate Capsule
Product Images NDC 0378-6856

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 0378-6856). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Lisdexamfetamine Dimesylate Structural Formula (Image 01)

Lisdexamfetamine Dimesylate Structural Formula (Image 01)
FDA Label Image

Figure 1: Specific Populations* (Image 02)

Figure 1: Specific Populations* (Image 02)
FDA Label Image

Figure 2: Effect Of Other Drugs On Lisdexamfetamine Dimesylate (Image 03)

Figure 2: Effect Of Other Drugs On Lisdexamfetamine Dimesylate (Image 03)
FDA Label Image

Figure 3: Effect Of Lisdexamfetamine Dimesylate On Other Drugs (Image 04)

Figure 3: Effect Of Lisdexamfetamine Dimesylate On Other Drugs (Image 04)
FDA Label Image

Figure 4: Ls Mean Skamp Deportment Subscale Score By Treatment And Time-point For Children Ages 6 To 12 With Adhd After 1 Week Of Double-blind Treatment (study 3) (Image 05)

Figure 4: Ls Mean Skamp Deportment Subscale Score By Treatment And Time-point For Children Ages 6 To 12 With Adhd After 1 Week Of Double-blind Treatment (study 3) (Image 05)
FDA Label Image

Figure 5: Kaplan-meier Estimated Proportion Of Patients With Treatment Failure For Pediatric Patients Ages 6 To 17 (study 6) (Image 06)

Figure 5: Kaplan-meier Estimated Proportion Of Patients With Treatment Failure For Pediatric Patients Ages 6 To 17 (study 6) (Image 06)
FDA Label Image

Figure 6: Ls Mean (se) Permp Total Score By Treatment And Time-point For Adults Ages 18 To 55 With Adhd After 1 Week Of Double-blind Treatment (study 8) (Image 07)

Figure 6: Ls Mean (se) Permp Total Score By Treatment And Time-point For Adults Ages 18 To 55 With Adhd After 1 Week Of Double-blind Treatment (study 8) (Image 07)
FDA Label Image

Figure 7: Kaplan-meier Estimated Proportion Of Subjects With Relapse In Adults With Adhd (study 9) (Image 08)

Figure 7: Kaplan-meier Estimated Proportion Of Subjects With Relapse In Adults With Adhd (study 9) (Image 08)
FDA Label Image

Figure 8: Kaplan-meier Estimated Proportion Of Subjects With Relapse In Adults With Bed (study 13) (Image 09)

Figure 8: Kaplan-meier Estimated Proportion Of Subjects With Relapse In Adults With Bed (study 13) (Image 09)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 10 mg Bottle Label (Image 10)

Lisdexamfetamine Dimesylate Capsules 10 mg Bottle Label (Image 10)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 20 mg Bottle Label (Image 11)

Lisdexamfetamine Dimesylate Capsules 20 mg Bottle Label (Image 11)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 30 mg Bottle Label (Image 12)

Lisdexamfetamine Dimesylate Capsules 30 mg Bottle Label (Image 12)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 40 mg Bottle Label (Image 13)

Lisdexamfetamine Dimesylate Capsules 40 mg Bottle Label (Image 13)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 50 mg Bottle Label (Image 14)

Lisdexamfetamine Dimesylate Capsules 50 mg Bottle Label (Image 14)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 60 mg Bottle Label (Image 15)

Lisdexamfetamine Dimesylate Capsules 60 mg Bottle Label (Image 15)
FDA Label Image

Lisdexamfetamine Dimesylate Capsules 70 mg Bottle Label (Image 16)

Lisdexamfetamine Dimesylate Capsules 70 mg Bottle Label (Image 16)